MX2021000711A - Metodo de produccion de derivado de tiazol. - Google Patents

Metodo de produccion de derivado de tiazol.

Info

Publication number
MX2021000711A
MX2021000711A MX2021000711A MX2021000711A MX2021000711A MX 2021000711 A MX2021000711 A MX 2021000711A MX 2021000711 A MX2021000711 A MX 2021000711A MX 2021000711 A MX2021000711 A MX 2021000711A MX 2021000711 A MX2021000711 A MX 2021000711A
Authority
MX
Mexico
Prior art keywords
sup
formula
production method
compound represented
thiazole derivative
Prior art date
Application number
MX2021000711A
Other languages
English (en)
Inventor
Takamasa Sugita
Arata Yanagisawa
Iwao Chujo
Masashi Taga
Akihiro Mimura
Atsushi Tada
Masashi Aoki
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of MX2021000711A publication Critical patent/MX2021000711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Se proporciona un método de producción de un derivado de tiazol representado por la fórmula (I), que tiene una acción antagonista del receptor A2A de adenosina y es útil como un agente terapéutico para, por ejemplo, enfermedad de Parkinson, trastornos del sueño, resistencia analgésica a opioides, migraña, trastorno del movimiento, depresión, trastorno de ansiedad y similares. También se proporciona un método de producción de un compuesto representado por la fórmula (C), que contiene (i) una etapa de reacción de un compuesto representado por la fórmula (A) y un compuesto representado por la fórmula (B), y similares: (ver Fórmulas) (donde R1 representa furilo, R4, R5 y R6 son los mismos o diferentes y cada uno representa alquilo inferior o arilo, R2 representa piridilo o tetrahidropiranilo, y X1 representa halógeno).
MX2021000711A 2015-01-09 2017-07-07 Metodo de produccion de derivado de tiazol. MX2021000711A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2015002964 2015-01-09

Publications (1)

Publication Number Publication Date
MX2021000711A true MX2021000711A (es) 2021-03-25

Family

ID=56356063

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009008A MX2017009008A (es) 2015-01-09 2016-01-08 Metodo de produccion de derivado de tiazol.
MX2021000711A MX2021000711A (es) 2015-01-09 2017-07-07 Metodo de produccion de derivado de tiazol.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017009008A MX2017009008A (es) 2015-01-09 2016-01-08 Metodo de produccion de derivado de tiazol.

Country Status (24)

Country Link
US (3) US10214523B2 (es)
EP (2) EP3822269A1 (es)
JP (2) JP6770962B2 (es)
CN (1) CN107108602B (es)
AR (1) AR103380A1 (es)
AU (1) AU2016205657B2 (es)
BR (1) BR112017014179A2 (es)
CA (2) CA3080031C (es)
CL (1) CL2017001695A1 (es)
CO (1) CO2017006204A2 (es)
DK (1) DK3242877T3 (es)
ES (1) ES2861050T3 (es)
HR (1) HRP20210385T1 (es)
HU (1) HUE053567T2 (es)
IL (2) IL252906B (es)
JO (2) JOP20200093A1 (es)
MX (2) MX2017009008A (es)
PL (1) PL3242877T3 (es)
PT (1) PT3242877T (es)
RS (1) RS61570B1 (es)
RU (2) RU2738937C2 (es)
SI (1) SI3242877T1 (es)
TW (2) TWI729810B (es)
WO (1) WO2016111381A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20200093A1 (ar) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول
CN109293652B (zh) * 2017-07-24 2021-10-22 四川科伦博泰生物医药股份有限公司 一种取代的噻唑衍生物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE445350B (sv) * 1978-04-14 1986-06-16 Roussel Uclaf Oximderivat av 3-azidometyl-7-amino-tiazolyl-acetamido-cefalosporansyra och dess anvendning som antibiotika
EA013249B1 (ru) * 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
ATE427941T1 (de) * 2004-07-27 2009-04-15 Astellas Pharma Inc Thiazolderivate mit vap-1-hemmender wirkung
US20100280023A1 (en) 2005-06-23 2010-11-04 Kyowa Hakko Kogyo Co., Ltd. Thiazole derivatives
TWI457125B (zh) 2005-08-02 2014-10-21 睡眠障礙之治療劑
US7776870B2 (en) 2005-08-22 2010-08-17 Melior Pharmaceuticals I, Inc. Methods for modulating Lyn kinase activity and treating related disorders
ZA200801857B (en) * 2005-08-31 2009-07-29 Astellas Pharma Inc Thiazole derivative
US20090281142A1 (en) 2005-08-31 2009-11-12 Astellas Pharma Inc. Thiazole derivative
TWI473614B (zh) 2008-05-29 2015-02-21 Kyowa Hakko Kirin Co Ltd Anti-analgesic inhibitors
CA2731573C (en) 2008-07-23 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Selective adenosine a2a receptor antagonists useful in the treatment and prevention of migraine
TWI548411B (zh) 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (uk) * 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
WO2012027965A1 (en) * 2010-09-01 2012-03-08 Glaxo Group Limited Novel compounds
JP6266270B2 (ja) 2013-05-20 2018-01-24 セイコーインスツル株式会社 運動フォーム解析装置および運動フォーム解析方法
JOP20200093A1 (ar) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd طريقة لإنتاج مشتق ثيازول

Also Published As

Publication number Publication date
TW202035397A (zh) 2020-10-01
IL252906A0 (en) 2017-08-31
EP3242877A1 (en) 2017-11-15
RU2017128217A3 (es) 2019-02-11
JP7068402B2 (ja) 2022-05-16
US10618894B2 (en) 2020-04-14
TW201639835A (zh) 2016-11-16
BR112017014179A2 (pt) 2018-03-06
JOP20200093A1 (ar) 2017-06-16
RS61570B1 (sr) 2021-04-29
CA2972746A1 (en) 2016-07-14
HRP20210385T1 (hr) 2021-04-16
PL3242877T3 (pl) 2021-05-31
CN107108602A (zh) 2017-08-29
DK3242877T3 (da) 2021-03-08
EP3242877A4 (en) 2018-10-17
AU2016205657A1 (en) 2017-07-13
TWI732748B (zh) 2021-07-11
CN107108602B (zh) 2021-08-03
US20180002326A1 (en) 2018-01-04
RU2017128217A (ru) 2019-02-11
US20190144438A1 (en) 2019-05-16
HUE053567T2 (hu) 2021-07-28
US20200216438A1 (en) 2020-07-09
RU2738937C2 (ru) 2020-12-18
IL252906B (en) 2020-03-31
CL2017001695A1 (es) 2018-03-23
JP2020193209A (ja) 2020-12-03
JO3546B1 (ar) 2020-07-05
CA2972746C (en) 2020-07-07
PT3242877T (pt) 2021-03-11
JP6770962B2 (ja) 2020-10-21
CO2017006204A2 (es) 2017-11-10
CA3080031A1 (en) 2016-07-14
SI3242877T1 (sl) 2021-04-30
JP2018501282A (ja) 2018-01-18
US10894790B2 (en) 2021-01-19
AR103380A1 (es) 2017-05-03
IL272811A (en) 2020-04-30
EP3822269A1 (en) 2021-05-19
ES2861050T3 (es) 2021-10-05
US10214523B2 (en) 2019-02-26
CA3080031C (en) 2022-04-12
TWI729810B (zh) 2021-06-01
RU2020141085A (ru) 2021-02-10
WO2016111381A1 (en) 2016-07-14
AU2016205657B2 (en) 2019-01-17
EP3242877B1 (en) 2020-12-16
MX2017009008A (es) 2017-09-27

Similar Documents

Publication Publication Date Title
PH12016501822A1 (en) Cyclopropaneamine compound
SA518391518B1 (ar) مشتقات n-] 2-(1- بنزيل ببريدين-4-يل) إيثيل[ -4-(بيرازين-2-يل)-ببرازين-1- كربوكساميد ومركبات متصلة بها كمضادات مستقبلة المسكارين 4 (m4) لمعالجة أمراض عصبية
IL256624A (en) Pharmaceuticals and their pharmaceutical preparations for the treatment of inflammatory disorders
PH12014502866A1 (en) Fungicidal heterocyclic carboxamides
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
MD3882250T2 (ro) Tetrahidropiranil-amino-pirolopirimidinona pentru utilizare într-un procedeu de tratament al unei tulburări mediate de BTK
SG10201900144TA (en) Pyridone derivative having tetrahydropyranylmethyl group
MX2016005759A (es) Derivados de piridina sustituidos, utiles como inhibidores de glucogeno sintasa cinasa 3 (gsk-3).
MX2016008536A (es) Derivados de fluoro-naftilo.
MX362102B (es) Método para producir 4-[5-(piridin-4-il)-1h-1,2,4-triazol-3-il]pir idina-2-carbonitrilo e intermediario del mismo.
MX2021000711A (es) Metodo de produccion de derivado de tiazol.
MX2016008898A (es) Antagonistas selectivos de nr2b.
IL264780B (en) A method for producing 2-(3,6-dihalopyridin-2-yl)-3h-imidazolo[4,5-c]pyridine derivatives and similar compounds by reacting a 3h-imidazolo[4,5-c]pyridine derivative with a base Organometallic zinc-amine
EA201791881A1 (ru) Производные 2-аминопиридина в качестве антагонистов рецептора аденозина aи лигандов рецепторов мелатонина mt
MX367267B (es) Proceso para preparar 3-(3-(4-(1-aminociclobutil)fenil)-5-fenil-3h -imidazo[4,5-b]piridin-2-il)piridin-2-amina.
TN2012000093A1 (en) Therapeutic agent for anxiety disorders
PH12015501056A1 (en) 2-pyridone compound
TW201613856A (en) Method for producing harmful-organism control agent, and intermediate thereof
MX2018004256A (es) Antagonistas de receptor de n-metil-d-aspartato subtipo 2b (nr2b) selectivos.
MX2016006482A (es) Derivado novedoso de 3-azabiciclo[3.1.0]hexano y uso del mismo para proposito medico.
EA201891038A1 (ru) Антагонисты мускаринового рецептора 4 и способы их применения
IN2013CH01070A (es)
NZ624722A (en) Novel 2h-indazoles as ep2 receptor antagonists
PL414227A1 (pl) Dimeryczne pochodne alkaloidów drzewa chinowego, sposób ich otrzymywania oraz ich zastosowanie
WO2014165633A8 (en) Cycloalkyl-dione derivatives and methods of their use